Monitor upcoming clinical data readouts in H1 2026 for EDG-7500 and EDG-15400, and the pivotal GRAND CANYON data in Q4 2026, which could be key value drivers for the stock.
Price Chart
Executive Summary
Edgewise Therapeutics reported Q4 2025 financial results with a net loss of $50.2 million and $530.1 million in cash. The company highlighted near-term catalysts including upcoming data readouts for EDG-7500 in HCM (H1 2026), EDG-15400 in heart failure (H1 2026), and pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy (Q4 2026).
Key Financial Metrics
Key Facts
- Cash, cash equivalents and marketable securities: $530.1 million as of December 31, 2025
- R&D expenses: $43.6 million for Q4 2025 (up from $37.5 million in Q3)
- G&A expenses: $12.4 million for Q4 2025 (up from $9.4 million in Q3)
- Net loss: $50.2 million or $0.47 per share for Q4 2025
- Upcoming catalysts: CIRRUS-HCM 12-week data (H1 2026), EDG-15400 Phase 1 data (H1 2026), GRAND CANYON pivotal data (Q4 2026)
Financial Impact
Net loss increased to $50.2 million in Q4 2025 from $40.7 million in Q3 2025, with R&D and G&A expenses both increasing significantly
Risk Factors
- Clinical trial results may not meet expectations
- Regulatory approval risks for sevasemten
- Need for substantial additional capital to finance operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-020108 |
| Document: tm266859d1_8k.htm | 0001104659-26-020108 |
| Document: 0001104659-26-020108-index-headers.html | 0001104659-26-020108 |
| Document: 0001104659-26-020108-index.html | 0001104659-26-020108 |
| Document: 0001104659-26-020108.txt | 0001104659-26-020108 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 6, 2026 8w ago | 8-K | $44.42 $41.95 | ▼ −5.56% | ▼ −6.16% | $41.22 (−7.20%) |
Jul 13, 2026 11w ago | 8-K | $41.27 $44.58 | ▲ +8.02% | ▲ +4.84% | $41.22 (−0.12%) |
Jun 1, 2026 17w ago | 8-K | $40.26 $40.63 | ▲ +0.92% | ▲ +2.22% | $41.22 (+2.38%) |
May 7, 2026 21w ago | 8-K | $35.58 $36.21 | ▲ +1.77% | ▼ −1.37% | $41.22 (+15.85%) |
Apr 23, 2026 23w ago | DEFA14A | $31.58 $32.69 | ▲ +3.51% | ▼ −0.51% | $41.22 (+30.53%) |
Mar 27, 2026 26w ago | 144 | $30.28 $30.99 | ▲ +2.34% | ▼ −10.25% | $41.22 (+36.13%) |
Feb 26, 2026 31w ago | 8-K | $29.66 $31.65 | ▲ +6.71% | ▲ +13.11% | $41.22 (+38.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access